The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
Open accessAbstract
Cancer-associated fibroblasts (CAFs), the principle component of the tumor-associated stroma, form a highly protumorigenic and immunosuppressive microenvironment that mediates therapeutic resistance. Co-targeting CAFs in addition to cancer cells may therefore augment the antitumor response. Fibroblast activation protein-α (FAP), a type 2 dipeptidyl peptidase, is expressed on CAFs in a majority of solid tumors making it an attractive immunotherapeutic target. To target FAP-positive CAFs in the tumor-associated stroma, we genetically modified T cells to express a FAP-specific chimeric antigen receptor (CAR). The resulting FAP-specific T cells recognized and killed FAP-positive target cells as determined by proinflammatory cytokine release and target cell lysis. In an established A549 lung cancer model, adoptive transfer of FAP-specific T cells significantly reduced FAP-positive stromal cells, with a concomitant decrease in tumor growth. Combining these FAP-specific T cells with T cells that targeted the EphA2 antigen on the A549 cancer cells themselves significantly enhanced overall antitumor activity and conferred a survival advantage compared to either alone. Our study underscores the value of co-targeting both CAFs and cancer cells to increase the benefits of T-cell immunotherapy for solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Stromal fibroblasts in cancer initiation and progression
Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004) · Nature · doi:10.1038/nature03096 · Cited by 2,302
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,163
Self-citationRooney, C. M., Smith, C. A., Ng, C. Y. C., Loftin, S. K., Sixbey, J. W., Gan, Y., Srivastava, D.-K., Bowman, L. C., Krance, R. A., Brenner, M. K., et al. (1998) · Blood · doi:10.1182/blood.v92.5.1549 · Cited by 1,135
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., et al. (1999) · Nature Medicine · doi:10.1038/9525 · Cited by 1,113
Savoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023
Self-citationTuxhorn, J. A., Ayala, G. E., Smith, M. J., Smith, V. C., Dang, T. D., & Rowley, D. R. (2002) · PubMed · Cited by 783
Self-citationGarin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748
Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633
Co-evolution of tumor cells and their microenvironment
Polyak, K., Haviv, I., & Campbell, I. G. (2009) · Trends in Genetics · doi:10.1016/j.tig.2008.10.012 · Cited by 628
Park, J. R., DiGiusto, D. L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet, H. B., Bautista, C., Chang, W.-C., Ostberg, J. R., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300104 · Cited by 603
Heterotypic Signaling between Epithelial Tumor Cells and Fibroblasts in Carcinoma Formation
Elenbaas, B., & Weinberg, R. A. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5133 · Cited by 558
Activation of fibroblasts in cancer stroma
Räsänen, K., & Vaheri, A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.04.032 · Cited by 499
Pulè, M. A., Straathof, K. C., Dotti, G., Heslop, H. E., Rooney, C. M., & Brenner, M. K. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.016 · Cited by 487
Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice
Santos, A. M., Jung, J., Aziz, N., Kissil, J. L., & Puré, E. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38988 · Cited by 428
Know thy neighbor: stromal cells can contribute oncogenic signals
Tlsty, T. D., & Hein, P. W. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00156-8 · Cited by 425
The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization
Ogawa, K., Pasqualini, R., Lindberg, R. A., Kain, R., Freeman, A. L., & Pasquale, E. B. (2000) · Oncogene · doi:10.1038/sj.onc.1204004 · Cited by 380
Hofheinz, R.-D., al-Batran, S.-E., Hartmann, F., Hartung, G., Jäger, D., Renner, C., Tanswell, P., Kunz, U., Amelsberg, A., Kuthan, H., et al. (2003) · Oncology Research and Treatment · doi:10.1159/000069863 · Cited by 374
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells
Zhang, B., Bowerman, N. A., Salama, J. K., Schmidt, H., Spiotto, M. T., Schietinger, A., Yu, P., Fu, Y.-X., Weichselbaum, R. R., Rowley, D. A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062056 · Cited by 359
Self-citationVera, J., Savoldo, B., Vigouroux, S., Biagi, E., Pule, M., Rossig, C., Wu, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017061 · Cited by 275
Therapeutic cancer vaccines: Are we there yet?
Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271
Rettig, W. J., Garin-Chesa, P., Beresford, H. R., Oettgen, H. F., Melamed, M. R., & Old, L. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.9.3110 · Cited by 271
Bystander elimination of antigen loss variants in established tumors
Spiotto, M. T., Rowley, D. A., & Schreiber, H. (2004) · Nature Medicine · doi:10.1038/nm999 · Cited by 260
Self-citationEffective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts
Ostermann, E., Garin-Chesa, P., Heider, K. H., Kalat, M., Lamche, H., Puri, C., Kerjaschki, D., Rettig, W. J., & Adolf, G. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5211 · Cited by 246
T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma
Chow, K. K., Naik, S., Kakarla, S., Brawley, V. S., Shaffer, D. R., Yi, Z., Rainusso, N., Wu, M.-F., Liu, H., Kew, Y., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.210 · Cited by 245
Self-citationPredictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival.
Kinch, M. S., Moore, M.-B. H., & Harpole, D. H. (2003) · PubMed · Cited by 235
Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-β Receptor
Foster, A. E., Dotti, G., Lu, A., Khalil, M., Brenner, M. K., Heslop, H. E., Rooney, C. M., & Bollard, C. M. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318177092b · Cited by 210
Shi, M. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i8.840 · Cited by 199
Gottschalk, S., Edwards, O. L., Sili, U., Huls, M. H., Goltsova, T., Davis, A. R., Heslop, H. E., & Rooney, C. M. (2003) · Blood · doi:10.1182/blood-2002-05-1514 · Cited by 186
Self-citationWen, Y., Wang, C., Ma, T., Li, Z., Zhou, L., Mu, B., Leng, F., Shi, H., Li, Y., & Wei, Y. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01695.x · Cited by 162
Saadi, A., Shannon, N. B., Lao-Sirieix, P., O’Donovan, M., Walker, E., Clemons, N. J., Hardwick, J. S., Zhang, C., Das, M., Save, V., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909797107 · Cited by 161
Lee, J., Fassnacht, M., Nair, S., Boczkowski, D., & Gilboa, E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2805 · Cited by 159
Vicent, S., Sayles, L. C., Vaka, D., Khatri, P., Gevaert, O., Ron, C., Zheng, Y., Gillespie, A. K., Clarke, N., Xu, Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1097 · Cited by 136
All in the Stroma: Cancer's Cosa Nostra
Marx, J. L. (2008) · Science · doi:10.1126/science.320.5872.38 · Cited by 78
Mentlein, R., Hattermann, K., Hemion, C., Jungbluth, A. A., & Held‐Feindt, J. (2010) · Biological Chemistry · doi:10.1515/bc.2010.119 · Cited by 78
Cunningham, C. C. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.9.1459 · Cited by 63
Brocks, B., Garin‐Chesa, P., Behrle, E., Park, J. E., Rettig, W. J., Pfizenmaier, K., & Moosmayer, D. (2001) · Molecular Medicine · doi:10.1007/bf03401851 · Cited by 62
Self-citationEngineered T cells for pancreatic cancer treatment
Katari, U. L., Keirnan, J. M., Worth, A. C., Hodges, S. E., Leen, A. M., Fisher, W. E., & Vera, J. F. (2011) · HPB · doi:10.1111/j.1477-2574.2011.00344.x · Cited by 61
The mesenchymal tumor microenvironment: A drug-resistant niche
Cukierman, E., & Bassi, D. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20210 · Cited by 46
FAP-α and uPA Show Different Expression Patterns in Premalignant and Malignant Esophageal Lesions
Goscinski, M. A., Suo, Z., Flørenes, V. A., Vlatkovic, L., Nesland, J. M., & Giercksky, K.-E. (2008) · Ultrastructural Pathology · doi:10.1080/01913120802034934 · Cited by 40
Targeting the tumour stroma to increase efficacy of chemo- and radiotherapy
Chometon, G., & Jendrossek, V. (2009) · Clinical & Translational Oncology · doi:10.1007/s12094-009-0317-y · Cited by 25
Cited by
Turning foes to friends: targeting cancer-associated fibroblasts
Chen, X., & Song, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,879
The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities
Ho, W. J., Jaffee, E. M., & Zheng, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0363-5 · Cited by 1,287
Targeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
Roybal, K. T., Rupp, L. J., Morsut, L., Walker, W. J., McNally, K. A., Park, J. S., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.01.011 · Cited by 1,000
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
Liu, T., Han, C., Wang, S., Fang, P., Ma, Z., Xu, L., & Yin, R. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0770-1 · Cited by 860
Metadata
- Authors
- Kakarla, S., Chow, K. K., Mata, M., Shaffer, D. R., Song, X.-T., Wu, M.-F., Liu, H., Wang, L. L., Rowley, D. R., Pfizenmaier, K., & Gottschalk, S.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 21
- Issue
- 8
- Pages
- 1611-1620
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2036144830
- Cited by
- 346
- References
- 47
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.